Peptide Companion
Back to catalog
Peptide Companion
single
Weight Management
Vial: 5 mg

Mazdutide (5 mg Vial)

Mazdutide (IBI362) is a long‑acting dual GLP‑1/glucagon receptor agonist developed for chronic weight management and type 2 diabetes. Phase 2 and 3 clinical trials have demonstrated substantial weight loss (6–14% reduction over 24–48 weeks) with mostly mild gastrointestinal side effects. This educational protocol presents a once‑weekly subcutaneous approach with practical dilution for clear insulin‑syringe measurements.

Dose
Research dosing varies (typically 3-6mg weekly)
Frequency
Once weekly
Timing
Any consistent time
Duration
12–24 weeks

Dual GLP-1/Glucagon agonist. Metabolic research. Gradual dose escalation recommended.

Dosing Schedule
WeekWeekly DoseUnits (per injection) (mL)
Weeks 1–42.5 mg (2,500 mcg)150 units (1.50 mL)
Weeks 5–8+5 mg (5,000 mcg)300 units (3.00 mL)
Supplies Needed
  • •Peptide Vials (Mazdutide, 5 mg each):
  • •Insulin Syringes (U‑100, 1 mL or 3 mL capacity):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for standard reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each week.
References

  • EClinicalMedicine (PubMed)

    Phase 1b trial: Safety and efficacy of mazdutide 9–10 mg in Chinese adults with overweight/obesity

    View source

  • Nature Communications

    Phase 2 randomized controlled trial of mazdutide in Chinese overweight/obese adults

    View source

  • New England Journal of Medicine

    Phase 3 trial: Once‑weekly mazdutide in Chinese adults with obesity or overweight (48‑week results)

    View source

  • Diabetes Care (PubMed)

    Phase 2 trial: Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes (20‑week results)

    View source

  • Frontiers in Endocrinology

    Systematic review and meta‑analysis: Efficacy and safety of mazdutide on weight loss (diabetic and non‑diabetic patients)

    View source

  • International Journal of Obesity (Nature)

    Review: Pipeline for future obesity medications (including mazdutide dual agonist mechanism)

    View source

  • Bachem Peptide Technical Guide

    Handling and storage guidelines for peptides (lyophilized and in solution)

    View source

  • CDC

    Vaccine administration: Subcutaneous injection technique (angle, site selection, no aspiration)

    View source

  • NCBI Bookshelf

    Clinical procedures: Subcutaneous injections (best practices and site rotation)

    View source

Educational content adapted from peptidedosages.com. Not medical advice.